TAT-10: Correspondence between alpha-particle emitter dosimetry and normal organ toxicity

Kanazawa, Japan (UroToday.com) Alpha particle doses are often very non-uniform within an organ so micro-dosimetry  with good resolution is necessary. This is not possible with human subjects so this study uses mice.

Healthy neu-N mice were injected intravenously with 15, 22, 30, and 44 KBq of Ac225-anti-PD-L1-BC. The mice were sacrificed when one of three conditions were met: >20% weight loss, evidence of pain or distress, the 100 day endpoint was reached.  The liver, spleen, kidneys, and thymus were removed and sectioned for imaging with an alpha camera [see next paper for a description of an alpha camera].

Liver and spleen received the highest doses: 738 and 615 mGy/kBq respectively. The kidneys received 138 mGy/kBq. The dose was uniform in the liver so macrodosimetry should give an accurate measure and the liver will determine the maximum tolerated dose. Activity was very non-uniform in the kidneys, spleen, and thymus. In the case of the kidneys, the non-uniformity may be attributed to a substantial contribution of the Bi213 which is preferentially absorbed in the renal cortex

Presented By: Anders Josefsson from Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.